Umberto Gianelli: Influence Statistics

Umberto Gianelli

Umberto Gianelli

Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy | Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, ...

Umberto Gianelli: Expert Impact

Concepts for which Umberto Gianelli has direct influence: Bone marrow , Primary myelofibrosis , Myeloproliferative neoplasms , Essential thrombocythemia , Myeloid neoplasms , European consensus , Systemic mastocytosis .

Umberto Gianelli: KOL impact

Concepts related to the work of other authors for which for which Umberto Gianelli has influence: Bone marrow , Myeloproliferative neoplasms , Cell lymphoma , Primary myelofibrosis , Myelodysplastic syndromes , Polycythemia vera , Essential thrombocythemia .

KOL Resume for Umberto Gianelli

Year
2022

Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

2021

Department of Pathophysiology and Transplantation, Università degli studi di Milano, 20122 Milan, Italy

2020

Pathology Unit, Department of Pathophysiology and Transplantation, University of Milan, IRCCS Ca’ Granda–Maggiore Policlinico, Hospital Foundation, Milan, Italy;

Department of Pathophysiology and Transplantation, Università degli Studi, Via Festa del Perdono 7, 20122 Milan, Italy

2019

Division of Pathology, Department of Pathophysiology and Transplantation, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, and University of Milan, Milan, Italy, View further author information

Pathology Unit, Department of Pathophysiology and Transplantation, University of Milan and IRCCS Fondazione Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy

2018

Hemopathology Unit IRCCS Ca' Granda Ospedale Maggiore Policlinico and University of Milan Milan Italy

2017

Pathology Unit, University of Milan Medical School, Fondazione IRCCS Cà Granda Ospedale Italy

2016

Hematopathology Service, Division of Pathology, Department of Pathophysiology and Transplantation, IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

2015

University of Milan and IRCCS Ca’ Granda – Maggiore Policlinico Hospital Foundation Haematopathology Service Division of Pathology Department of Pathophysiology and Transplantation Milan Italy

2014

and University of Milan, Milan, Italy

2013

Division of Pathology, Department of Pathophysiology and Transplantation, University of Milan Medical School, IRCCS Ca’ Granda-Ospedale Maggiore Policlinico Foundation, Milan, Italy

2012

Pathology Unit, Department of Pathophysiology and Transplantation, University of Milan Medical School, IRCCS Ca’ Granda—Ospedale Maggiore Policlinico Foundation, Milano, Italy

2011

Pathology Unit, Department of Medicine, Surgery and Dentistry, University of Milan Medical School, IRCCS Ca’ Granda – Ospedale Maggiore Policlinico Foundation, via Sforza, 28, 20122, Milan, Italy

2010

University of Milan, Milan, Italy

2009

Department of Pathology, University of Milan and San Paolo Hospital, Milan, Italy

2008

Pathology Unit, Department of Medicine, Surgery and Odontology, San Paolo Hospital, and “Policlinico IRCCS” Hospital, Mangiagalli and Regina Elena Foundation, University of Milan

2007

II Cattedra di Anatomia Patologica, Dipartimento di Medicina, Chirurgia, E Odontoiatria (DMCO), A. O. San Paolo, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan;

Pathology Unit, Department of Medicine, Surgery and Odontology, San Paolo Hospital, and Policlinico IRCCS Hospital, Mangiagalli and Regina Elena Foundation, University of Milan, Italy

2006

II Cattedra di Anatomia Patologica, Dipartimento di Medicina, Chirurgia e Odontoiatria, Università degli Studi di Milano, A. O. S. Paolo e Fondazione Ospedale Maggiore Policlinico, Via Di Rudini’, 8, 20142, Mangiagalli e Regina Elena di Milano, Italy

2005

Institute of Dermatological Sciences, University of Milan – IRCCS Ospedale Maggiore of Milan, Department of Pathology, University of Milan, Ospedale San Paolo, and, Dermatologic Unit, University of Milano Bicocca, Milan, Italy

2004

From the *Postgraduate School of Gastroenterology, ‡Hematology Unit and †Pathology Unit, University of Milan, IRCCS - Ospedale Maggiore and Ospedale S. Paolo, Milan, Italy

Prominent publications by Umberto Gianelli

KOL-Index: 11980 . The diagnosis of an underlying chronic myeloproliferative disorder (CMPD) is often problematic in patients with primary extrahepatic portal vein obstruction (EHPVO) or Budd-Chiari syndrome (BCS); indeed, conventional clinical and hematological parameters usually yield insufficient information. To assess the diagnostic contribution of the gain-of-function mutation V617F of the JAK2 gene, 93 ...
Known for Jak2 Mutation | Splanchnic Vein Thrombosis | Ehpvo Bcs | Chronic Myeloproliferative
KOL-Index: 11749 . AIMS: The authors investigated vascular endothelial growth factor receptor 1 (VEGFR-1) protein expression in a series of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph- MPNs) and its correlations with microvessel density (MVD) and vascular endothelial growth factor (VEGF). METHODS: 83 bone marrow biopsies of Ph- MPNs patients, including 27 essential thrombocythaemia ...
Known for Vascular Endothelial | Growth Factor | Microvessel Density | Vegf Vegfr1
KOL-Index: 10913 . OBJECTIVE: Inflammatory bowel diseases are characterized by disorders of immunity, thrombosis of large vessels, and microthrombosis of mucosal vessels. The expression of endothelial protein C receptor (EPCR) and thrombomodulin-two receptors of the protein C pathway involved in thrombin scavenging and inflammation-was studied in intestinal resection specimens or mucosal biopsies from ...
Known for Inflammatory Bowel Disease | Endothelial Protein | Epcr Thrombomodulin | Aged Antigens
KOL-Index: 10428 . Alemtuzumab is active in chronic lymphocytic leukaemia (CLL) patients refractory to alkylators and fludarabine. The aim of this study was to determine the efficacy and safety of subcutaneous alemtuzumab at low dose (10 mg three times per week, for 18 weeks) to 49 patients with pre-treated CLL. The overall response rate was 53%, including 27% of complete responses; it was 42% in patients ...
Known for Alemtuzumab Antibodies | Chronic Lymphocytic | Low Dose | Cll Patients
KOL-Index: 9573 . Approximately one-fourth of patients with essential thrombocythemia or primary myelofibrosis carry a somatic mutation of the calreticulin gene (CALR), the gene encoding for calreticulin. A 52-bp deletion (type I mutation) and a 5-bp insertion (type II mutation) are the most frequent genetic lesions. The mechanism(s) by which a CALR mutation leads to a myeloproliferative phenotype has been ...
Known for Mutant Calreticulin | Myeloproliferative Neoplasms | Megakaryocytes Mks | Calr Mutation
KOL-Index: 9488 . BACKGROUND AND OBJECTIVES: This study explored variations in the clinical manifestations of intravascular lymphoma (IVL) on the bases of the association with hemophagocytosis and the country where the diagnosis was made. DESIGN AND METHODS: The clinical features of 50 Western patients with IVL were compared with those of 123 patients with IVL diagnosed in Eastern countries (87 diagnosed in ...
Known for Intravascular Lymphoma | Clinical Presentation | Large Bcell | Western Patients
KOL-Index: 9126 . Breast implant-associated anaplastic large cell lymphoma is a new provisional entity in the revised World Health Organization classification of lymphoid malignancies, the pathogenesis and cell of origin of which are still unknown. We performed gene expression profiling of microdissected breast implant-associated anaplastic large cell lymphoma samples and compared their transcriptional ...
Known for Large Cell | Breast Implant | Anaplastic Lymphoma | Transcriptional Analysis
KOL-Index: 8761 . We investigated the relationship between the International Prognostic Scoring System of the International Working Group for Myelofibrosis Research and Treatment and the European Consensus on grading of bone marrow fibrosis (MF) in patients with primary myelofibrosis. We compared them in 196 consecutive primary myelofibrosis patients (median follow-up 45.7 months; range 7.4–159). ...
Known for Bone Marrow | Primary Myelofibrosis | European Consensus | Mf Patients
KOL-Index: 8125 . The expression of zeta-associated protein 70 (ZAP-70) in chronic lymphocytic leukemia (CLL) seems to correlate with the mutational status of the immunoglobulin heavy-chain variable-region genes, clinical course and patient prognosis. The aim was to determine the prognostic significance of the immunohistochemical expression of ZAP-70 protein in CLL by means of the long-term follow-up of 108 ...
Known for Chronic Lymphocytic | Prognostic Marker | Zap70 Protein | Cll Patients
KOL-Index: 7370 . Increased angiogenesis has been demonstrated to be a significant prognostic factor in many solid tumors. In the oncohematological setting, it has been associated with myelodysplastic syndromes (MDS), chronic myeloid leukemia, acute lymphoid, and myeloid leukemias. Recently, increased circulating endothelial cells (CECs) have been associated with breast cancer and non-Hodgkin lymphoma ...
Known for Myelodysplastic Syndromes | Endothelial Cells | Peripheral Blood | Cecs Ceps
KOL-Index: 7244 . We examined microvessel density (MVD) and immunohistochemical expression of vascular endothelial growth factor (VEGF) in the bone marrow biopsy specimens of 98 patients with Philadelphia chromosome-negative (Ph-) chronic myeloproliferative disorders (CMPDs). There were significantly more MVD "hot spots" in chronic idiopathic myelofibrosis (CIMF; mean +/- SD, 25.6 +/- 6.3) and polycythemia ...
Known for Microvessel Density | Vegf Expression | Myeloproliferative Disorders | Bone Marrow
KOL-Index: 7185 . The World Health Organization classification of myelodysplastic syndromes (MDS) is based on morphological evaluation of marrow dysplasia. We performed a systematic review of cytological and histological data from 1150 patients with peripheral blood cytopenia. We analyzed the frequency and discriminant power of single morphological abnormalities. A score to define minimal morphological ...
Known for Marrow Dysplasia | Myelodysplastic Syndromes | Health Organization Mds | Myeloid Neoplasms
KOL-Index: 7168 . It has been suggested that polycythemia vera (PV) could be preceded by an "early" phase of the disease (e-PV), in which the increase in the red cell parameters is lower than required for a PV diagnosis. In this study, we compared the clinicopathologic and molecular features of 17 patients with e-PV with those of 14 patients with essential thrombocythemia (ET) and 19 with PV. The results ...
Known for Polycythemia Vera | Essential Thrombocythemia | Jak2v617f Mutation | Bone Marrow

Key People For Bone Marrow

Top KOLs in the world
#1
Irving Lerner Weissman
stem cells bone marrow inbred balb mice
#2
Rainer F Rainer
marrow transplantation host disease aplastic anemia
#3
Darwin J Prockop
osteogenesis imperfecta stem cells transgenic mice
#4
E Donnal L Thomas
marrow transplantation host disease aplastic anemia
#5
David T Scadden
bone marrow stem cell multiple myeloma
#6
Mark F Pittenger
stem cells myocardial infarction bone marrow

Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy | Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy;, umberto.gianelli@unimi.it | Department of Pathophysiology and Transpla